Zimmer Biomet to buy Paragon 28 for $1.1 billion

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 29, 2025

Zimmer Biomet to buy Paragon 28 for $1.1 billion

(Reuters) -Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion to expand its portfolio of orthopedic surgical devices.

The deal will give Zimmer Biomet access to Paragon's surgical implants and equipment used to treat foot and ankle ailments, while bolstering its fracture and trauma, and joint replacement businesses.

Under the terms of the deal, Zimmer Biomet will make an upfront payment of $13.00 per share in cash, which represents an 8.3% premium to Paragon's closing price on Tuesday.

Shares of Paragon 28 rose 9.3% in extended trading.

Paragon stockholders will also receive a non-tradeable contingent value right for up to $1 per share based on achievements, Zimmer said, potentially raising the deal value to around $1.2 billion.

Zimmer plans to fund the transaction through a combination of cash and debt financing and expects to close it in the first half of 2025.

It expects the deal to be about 3% dilutive to its 2025 adjusted profit.

(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona)

Recommended for you